Pharmaceutical News

RSS

Capsules: IOM recommends free birth control for all

Today on the Capsules blog, Jenny Gold writes: American women ought to be able to get their birth control for free, according to a new report from the Institute of Medicine.

20 Jul 2011

Birth control pills may reduce woman's bone density

Birth control pills may reduce a woman's bone density, according to a study published online July 13 in The Journal of Clinical Endocrinology and Metabolism by Group Health Research Institute (GHRI) scientists.

20 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Valeant, sanofi-aventis partner to market and distribute Zuacta cream

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL, has entered into an agreement with sanofi-aventis Canada Inc.

20 Jul 2011

Patients who use anti-depressants more likely to suffer relapses

Patients who use anti-depressants are much more likely to suffer relapses of major depression than those who use no medication at all, concludes a McMaster researcher.

20 Jul 2011

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

CEL-SCI Corporation announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.

20 Jul 2011

DNA vaccine developer Coridon in U.S. collaboration

DNA vaccine development company Coridon Pty Ltd. today announced that it has entered into a research collaboration agreement with The Ohio State University to progress its Epstein Barr Virus (EBV) project.

19 Jul 2011

Natural formula can fight against highly invasive breast cancer

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.

19 Jul 2011

Thalidomide analog shows promise against sickle cell disease

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

19 Jul 2011

Catylix, Illinois enter license agreement to incorporate fluorine into drugs

Catylix, Inc. and the University of Illinois at Urbana-Champaign have entered into a license agreement under which Catylix will utilize a technology developed by Illinois' Professor John Hartwig to quickly and efficiently introduce fluorine and fluorine-containing substituents into molecules.

19 Jul 2011

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

In a study published recently in the journal Science Signaling Van Andel Research Institute (VARI) scientists demonstrate on the molecular level how the anti-malaria drug chloroquine represses inflammation, which may provide a blueprint for new strategies for treating inflammation and a multitude of autoimmune diseases such as arthritis, multiple sclerosis, and certain cancers.

19 Jul 2011

U.S. Patent Office issues Notice of Allowance for Kuros' PTH to improve bone healing

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office.

19 Jul 2011

International Journal of Cancer publishes Bionovo's Bezielle research

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the publication of a study of the metabolic effects of its drug candidate, Bezielle, on cancer cells in the International Journal of Cancer.

19 Jul 2011

Optimer introduces DIFICID for treatment of C. difficile-associated diarrhea

Optimer Pharmaceuticals, Inc. today announced the commercial launch of DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older.

19 Jul 2011

U.S. FDA approves 2011-2012 influenza vaccine formulation

The U.S. Food and Drug Administration announced today that it has approved the influenza vaccine formulation for the 2011-2012 vaccine that will be used by the six manufacturers licensed to produce and distribute influenza vaccine for the United States.

19 Jul 2011

FDA approves Lannett's Diethylproprion HCl Tablets ANDA for anti-obesity treatment

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) of Diethylproprion HCl Tablets, 25 mg. Diethylproprion HCl Tablets, 25 mg, is therapeutically equivalent to the reference listed drug, Tenuate Tablets, 25 mg, of Watson Pharmaceuticals.

19 Jul 2011

Flu vaccine for 2011-12 season approved and ready

According to an announcement from the Food and Drug Administration (FDA) on Monday, it has approved the new flu vaccine for the season beginning this year. Each year the FDA works with other federal agencies and global health experts to design a vaccine to protect against the three viral strains most likely to cause the flu.

19 Jul 2011

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

Graceway Pharmaceuticals, LLC announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment of actinic keratoses, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses.

19 Jul 2011

Shionogi to acquire Victory Pharma's products to treat pain and infectious diseases

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.

18 Jul 2011

CSL Behring supports World Federation of Hemophilia with 1 million IUs of von Willebrand factor/Factor VIII

CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII (FVIII) replacement medication to patients through the World Federation of Hemophilia (WFH). The donation supports WFH's progress in improving the diagnosis and treatment of bleeding disorders in developing countries through its Global Alliance for Progress (GAP) program.

18 Jul 2011